These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 23679904)
21. A review of tigecycline--the first glycylcycline. Peterson LR Int J Antimicrob Agents; 2008 Dec; 32 Suppl 4():S215-22. PubMed ID: 19134522 [TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Van Wart SA; Owen JS; Ludwig EA; Meagher AK; Korth-Bradley JM; Cirincione BB Antimicrob Agents Chemother; 2006 Nov; 50(11):3701-7. PubMed ID: 16940069 [TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. Sacchidanand S; Penn RL; Embil JM; Campos ME; Curcio D; Ellis-Grosse E; Loh E; Rose G Int J Infect Dis; 2005 Sep; 9(5):251-61. PubMed ID: 16099700 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Giamarellou H; Poulakou G Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1459-70. PubMed ID: 21958044 [TBL] [Abstract][Full Text] [Related]
25. Anti-anaerobic activity of serum from patients treated with tigecycline for skin/soft tissue infections. Stein GE; Tyrrell KL; Dybas LA; Citron DM; Nicolau DP; Goldstein EJ Anaerobe; 2011 Aug; 17(4):213-5. PubMed ID: 21376823 [TBL] [Abstract][Full Text] [Related]
27. Re-defining tigecycline therapy. De Rosa FG; Corcione S; Di Perri G; Scaglione F New Microbiol; 2015 Apr; 38(2):121-36. PubMed ID: 25915055 [TBL] [Abstract][Full Text] [Related]
28. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Meagher AK; Passarell JA; Cirincione BB; Van Wart SA; Liolios K; Babinchak T; Ellis-Grosse EJ; Ambrose PG Antimicrob Agents Chemother; 2007 Jun; 51(6):1939-45. PubMed ID: 17353238 [TBL] [Abstract][Full Text] [Related]
29. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Curcio D; Fernández F; Cané A; Barcelona L; Stamboulian D Braz J Infect Dis; 2008 Jun; 12(3):198-201. PubMed ID: 18833403 [TBL] [Abstract][Full Text] [Related]
30. Clinical characteristics of patients with community-acquired complicated intra-abdominal infections: a prospective, multicentre, observational study. Jean SS; Ko WC; Xie Y; Pawar V; Zhang D; Prajapati G; Mendoza M; Kiratisin P; Ramalheira E; Castro AP; Rosso F; Hsueh PR Int J Antimicrob Agents; 2014 Sep; 44(3):222-8. PubMed ID: 25106073 [TBL] [Abstract][Full Text] [Related]
31. Tigecycline: a review of a new glycylcycline antibiotic. Scheinfeld N J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141 [TBL] [Abstract][Full Text] [Related]
32. Tigecycline: a new antibiotic. Hylands J Intensive Crit Care Nurs; 2008 Aug; 24(4):260-3. PubMed ID: 18554910 [TBL] [Abstract][Full Text] [Related]
33. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance? Fraise AP J Infect; 2006 Nov; 53(5):293-300. PubMed ID: 16876253 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study. Gonzalez-Ruiz A; Beiras-Fernandez A; Lehmkuhl H; Dohmen PM; Loeffler J; Chaves RL Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225 [TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Logman JF; Stephens J; Heeg B; Haider S; Cappelleri J; Nathwani D; Tice A; van Hout BA Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820 [TBL] [Abstract][Full Text] [Related]
36. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients. Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Falagas ME; Vardakas KZ; Tsiveriotis KP; Triarides NA; Tansarli GS Int J Antimicrob Agents; 2014 Jul; 44(1):1-7. PubMed ID: 24602499 [TBL] [Abstract][Full Text] [Related]
38. Guideline summary: appropriate use of tigecycline. Brink AJ; Bizos D; Boffard KD; Feldman C; Grolman DC; Pretorius J; Richards GA; Steyn E S Afr J Surg; 2012 Feb; 50(1):20-1. PubMed ID: 22353316 [TBL] [Abstract][Full Text] [Related]
39. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. Sader HS; Mallick R; Kuznik A; Fritsche TR; Jones RN Int J Antimicrob Agents; 2007 Dec; 30(6):514-20. PubMed ID: 17959359 [TBL] [Abstract][Full Text] [Related]